Senhwa Biosciences, Inc.
Research Senhwa Biosciences, Inc. (6492.TWO) on Bullrun: market cap TWD 3.84B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6492.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 3.84B
- Financial periodQ2 2026
- RevenueTWD 240.00K
- Net income-TWD 82.46M
- Free cash flow-TWD 49.46M
- Gross margin56.3%
Valuation Snapshot
latest market cap is TWD 3.84B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 3.84B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Senhwa Biosciences, Inc.
Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II);
ETFs that hold Senhwa Biosciences, Inc.
US-listed ETFs
Senhwa Biosciences, Inc. is held by 2 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.02% | 0.65% |
| State Street SPDR S&P Emerging Asia Pacific ETF (GMF) | <0.01% | 0.49% |
Portfolios as filed with the SEC on Form N-PORT, dated June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Senhwa Biosciences, Inc.'s market cap?
Senhwa Biosciences, Inc.'s market capitalization is TWD 3.84B.
What does Senhwa Biosciences, Inc. do?
Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. It also provides technical advice and consulting services.